SSA
RARE icon

Schonfeld Strategic Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,000
Closed -$529K – 2588
2025
Q4 		$529K Buy
+23,000
New +$756K ﹤0.01% 1375
2025
Q1 		– Sell
-50,000
Closed -$2.1M – 2450
2024
Q4 		$2.1M Buy
+50,000
New +$2.48M 0.01% 811

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Schonfeld Strategic Advisors's RARE Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 33% in Q1 2026, selling an estimated $5.56M and leaving 494,737 shares worth $10.4M. The position accounts for 0.07% of the portfolio, ranked #289.

Schonfeld Strategic Advisors first reported a position in RARE in Q1 2017 and has held it in 21 quarters since. The position peaked at $34.4M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Schonfeld Strategic Advisors held 494,737 shares of Ultragenyx Pharmaceutical worth $10.4M as of Q1 2026.
  • Schonfeld Strategic Advisors sold 246,881 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.56M.
  • Ultragenyx Pharmaceutical made up 0.07% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #289 holding.
  • Schonfeld Strategic Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 21 quarters since.
  • Schonfeld Strategic Advisors's Ultragenyx Pharmaceutical position peaked at $34.4M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.